Publications by authors named "Robert Millham"

Claim this Profile
A
A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors.
Emiliano Calvo, Jean-Charles Soria, Wen Wee Ma, Tao Wang, Rastilav Bahleda, Robert Millham

Clin Cancer Res· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer.
Geoffrey I Shapiro, Katherine M Bell-McGuinn, Julian R Molina, Johanna Bendell, James Spicer, Robert Millham

Clin Cancer Res· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer.
Carolyn D Britten, Alex A Adjei, Robert Millham, Brett E Houk, Gary Borzillo

Invest New Drugs· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors.
Pasi A Jänne, David S Boss, D Ross Camidge, Carolyn D Britten, Jeffrey A Engelman, Robert Millham

Clin Cancer Res· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of inhibitors of the IGF-IR/PI3K/Akt/mTOR pathway.
Mary L Hixon, Luisa Paccagnella, Robert Millham, Raul Perez-Olle, Antonio Gualberto

Rev Recent Clin Trials· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer.
Antoni Ribas, Douglas C Hanson, Dennis A Noe, Robert Millham, Deborah J Guyot

Oncologist· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy.
Donghua Yin, Franzanne Vreeland, Larry J Schaaf, Robert Millham, Barbara A Duncan

Clin Cancer Res· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fit-for-purpose method development and validation for successful biomarker measurement.
Jean W Lee, Viswanath Devanarayan, Yu Chen Barrett, Russell Weiner, John Allinson, Robert Millham

Pharm Res· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
Antoni Ribas, Luis H Camacho, Gabriel Lopez-Berestein, Dmitri Pavlov, Cecile A Bulanhagui, Robert Millham

J Clin Oncol· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis